<DOC>
	<DOCNO>NCT02028650</DOCNO>
	<brief_summary>The relapse leukemia patient transplantation divide two group randomly . Group D1 : patient receive first-donor stem cell infusion ( DSI ) treatment without chemotherapy ; group D2 : patient receive second-donor DSI treatment without chemotherapy . The second donor preferably donor genetically relate HLA-match locus . The re-induction chemotherapy regimen primarily MAT ( mitoxantrone , cytarabine , Teniposide ) acute myeloid leukemia ( AML ) VMCLD ( vincristine , Teniposide , cyclophosphamide , L-Asparaginase , Dexamethasone ) acute lymphocytic leukemia ( ALL ) , graft versus host disease ( GVHD ) prevention conduct pre- post- therapy .</brief_summary>
	<brief_title>Randomized Study HLA-mismatched DSI Treat Relapse Leukemia After HLA- Matched Transplantation</brief_title>
	<detailed_description>Evaluation indication include bone marrow morphology , hematopoietic recovery ( neutrophil platelet ) , 100-day transplantation-related mortality ( TRM ) , donor chimerism , acute GVHD , chronic GVHD , disease free survival ( DFS ) , overall survival ( OS ) . The cut-time follow-up Oct , 2013 . DFS define time date transplantation death relapse . OS define time diagnosis death last date follow-up Oct. 2013 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Eligible patient 9 67 year age de novo diagnose treatedrelated Acute leukemia relapse HLAmatched hematological stem cell transplantation Feb 2005 Feb 2013 Relapse morphologically molecularly diagnose , help cytogenetic engraftment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients without receive CR receive postremission trial therapy The patient AMLM3 exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>relapse leukemia</keyword>
	<keyword>DSI</keyword>
</DOC>